- Home
- VNO vs RYTM Comparison
VNO vs RYTM Comparison
Compare VNO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VNO | RYTM |
|---|---|---|
| Founded | 1946 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.1B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VNO | RYTM |
|---|---|---|
| Price | $31.88 | $102.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $37.50 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 1.3M | 584.7K |
| Earning Date | 02-09-2026 | 02-25-2026 |
| Dividend Yield | ★ 2.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 4.20 | N/A |
| Revenue | ★ $1,903,939,000.00 | $174,334,000.00 |
| Revenue This Year | N/A | $47.78 |
| Revenue Next Year | $1.85 | $56.52 |
| P/E Ratio | $7.59 | ★ N/A |
| Revenue Growth | 1.75 | ★ 54.92 |
| 52 Week Low | $29.68 | $45.91 |
| 52 Week High | $45.37 | $122.20 |
Technical Indicators
Market Signals| Indicator | VNO | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 38.17 | 46.17 |
| Support Level | $30.98 | $101.21 |
| Resistance Level | $32.34 | $105.95 |
| Average True Range (ATR) | 0.78 | 5.16 |
| MACD | -0.12 | -0.16 |
| Stochastic Oscillator | 24.83 | 21.28 |
Price Performance
Historical ComparisonAbout VNO Vornado Realty Trust
Vornado owns and has an ownership interest in Class A office and retail properties highly concentrated in Manhattan, with additional properties in San Francisco and Chicago. It operates as a real estate investment trust.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.